Evidence map›Paper›PMID 34671555›Full record

ArticleFrontiers in oncology2021

Exosome Released FZD10 Increases Ki-67 Expression

Maria Principia Scavo, Federica Rizzi, Nicoletta Depalo, Raffaele Armentano, Sergio Coletta, Grazia Serino, Elisabetta Fanizza, Pasqua Letizia Pesole, Alessandra Cervellera, Nicola Carella and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Maria Principia ScavoPersonalized Medicine Laboratory, National Institute of Gastroenterology "S. De Bellis" Research Hospital, Bari, Italy.
Federica RizziUniversity of Bari "A. Moro," Chemistry Department, Bari, Italy.
Nicoletta DepaloInstitute for Chemical-Physical Processes (IPCF)-National Research Council Secondary Site (CNR SS) Bari, Bari, Italy.
Raffaele ArmentanoDepartment of Pathology, National Institute of Gastroenterology "S. de Bellis," Research Hospital, Bari, Italy.
Sergio ColettaDepartment of Pathology, National Institute of Gastroenterology "S. de Bellis," Research Hospital, Bari, Italy.
Grazia SerinoExperimental Immunopathology Laboratory, National Institute of Gastroenterology "S. de Bellis," Research Hospital, Bari, Italy.
Elisabetta FanizzaUniversity of Bari "A. Moro," Chemistry Department, Bari, Italy.
Pasqua Letizia PesoleLaboratory of Clinical Pathology, National Institute of Gastroenterology, "S de Bellis" Research Hospital, Bari, Italy.
Alessandra CervelleraLaboratory of Clinical Pathology, National Institute of Gastroenterology, "S de Bellis" Research Hospital, Bari, Italy.
Nicola CarellaLaboratory of Clinical Pathology, National Institute of Gastroenterology, "S de Bellis" Research Hospital, Bari, Italy.
Maria Lucia CurriUniversity of Bari "A. Moro," Chemistry Department, Bari, Italy.
Gianluigi GiannelliScientific Direction, National Institute of Gastroenterology "S. De Bellis" Research Hospital, Bari, Italy.
Gastroenterology Hospital "Saverio de Bellis" · ITUniversity of Bari Aldo Moro · ITInstitute for Chemical and Physical Processes · ITNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frizzled (FZD) proteins are primary receptors for Wnt signaling that activates the mitogen-activated protein kinase (MAPK) pathways. Dysfunction of Wnt signals with consequently abnormal activation of MAPK3 pathways was found in colorectal cancer (CRC) and gastric cancer (GC). Upregulation of FZD10 protein, localized in the exosomes isolated from plasma of CRC and GC patients, was associated with a poor prognosis. Herein, the expression levels of circulating FZD10 were found to be strongly correlated to their expression levels in the corresponding tissues in CRC and GC patients. Bioinformatic prediction revealed a link between FZD10 and Ki-67 through MAPK3. In both CRC and GC tissues, pERK1/2 levels were significantly increased at more advanced disease stages, and pERK1/2 and Ki-67 were correlated. Silencing of FZD10 in CRC and GC cells resulted in a significant reduction of pERK1/2 and Ki-67 expression, while subsequent treatment with exogenous exosomes partially restored their expression levels. The strong correlation between the expression of Ki-67 in tissues and of FZD10 in exosomes suggests that the exosome-delivered FZD10 may be a promising novel prognostic and diagnostic biomarker for CRC and GC.

Indexed as

colorectal cancerexosomesFZD10gastric cancerKi-67MAPK/ERK

Identifiers

PMID34671555
PMCPMC8522497
OpenAlexW3204014435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.